Abstract 4143
Background
Cancer incidence is increasing but cancer survival is improving. The life expectancy of PLWHIV also increases with improved HAART, so it is to be expected that PLWHIV are likely to develop a second primitive cancer. It is known that the risk of second cancer is slightly higher after a first cancer and depends on several parameters: the location of the first cancer (the risk is higher after H&N, lung cancer or Hodgkin’s lymphoma) and environmental risk factors such as tobacco or alcohol intake but few studies are available nowadays on this subject. PLWHIV have a high risk of cancer: what for a second cancer incidence?
Methods
The files of 601 patients presented at the multidisciplinary meeting of the CANCERVIH network were reviewed. CANCERVIH is a national "rare cancers" network, accredited by the French National Cancer Institute. For all these patients, the history of cancer, indicated by the referring physicians, was examined. History of cancer that was neither metastasis nor locoregional relapse was considered a first primitive cancer. Cancers developing in the same location were considered as first primitive cancers only if they were considered in complete response at least 5 years before and no relapse was detected in the meantime.
Results
Of the 601 patients reviewed, 72 (12%) had a history of at least one cancer. Fourteen (2,3%) patients had at least 2 previous cancers. For one it was his 7th cancer’s case.Table:
2036P
First cancer (number of patients) | Number of secondary cancer(s) (number of patients) |
---|---|
Kaposi (25) | 1 (23) 2 (2) |
NHL (7) | 1 (5) 2 (2) |
Anal canal (6) | 1 (2) 2 (3) 3 (1) |
Prostate (6) | 1 (4) 2 (1) 6 (1) |
Breast (5) | 1 (5) |
Head and Neck (5) | 1 (4) 4 (1) |
Hodgkin lymphoma (4) | 1 (4) |
Kidney (4) | 1 (3) 2 (1) |
Skin melanoma (3) | 1 (2) 2 (1) |
Eye (2) | 1 (1) 3 (1) |
Anal margin (1) | 1 (1) |
Lung (1) | 1 (1) |
Ovary (1) | 1 (1) |
Large intestine (1) | 2 (1) |
Liver (1) | 1 (1) |
Conclusions
In this study, the initial locations at risk of second cancer seems to concern primarily AIDS defining cancer and among the non-AIDS defining cancers, anal cancer appeared the first one ahead breast and head and neck cancers, showing the importance of maintaining permanent immuno-virological control in these patients’ population: such results confirm the need to maintain and emphasize prevention and screening programs in this high cancer risk population including for those with a sustained undetectable HIV viral load and/or immune restoration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045 - The analysis of treatment sequences and clinical outcomes of thymic carcinoma
Presenter: Arakaki Motoko
Session: Poster Display session 1
Resources:
Abstract
4785 - Transcriptomic Difference of Thymoma and Thymic Carcinoma
Presenter: Naixin Liang
Session: Poster Display session 1
Resources:
Abstract
2864 - A Phase II Trial of Preoperative Chemoradiotherapy and Pembrolizumab for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Presenter: Seoyoung Lee
Session: Poster Display session 1
Resources:
Abstract
5015 - The study of tumor associated exosomes in crosstalk between esophageal carcinoma and lymphatic endothelial cells
Presenter: Weimin Mao
Session: Poster Display session 1
Resources:
Abstract
1339 - Up-regulation of IBSP expression predicts poor prognosis of Esophageal Squamous Cell Carcinoma patients
Presenter: Mingyue Wang
Session: Poster Display session 1
Resources:
Abstract
4083 - PD-L1 expression in primary tumour vs metastatic samples in the Phase 3 MYSTIC study in first-line metastatic (m) NSCLC
Presenter: Niels Reinmuth
Session: Poster Display session 1
Resources:
Abstract
5113 - Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: post hoc analyses from the phase 3 JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
4256 - Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): post hoc analyses from JAVELIN Solid Tumor
Presenter: Borys Hrinczenko
Session: Poster Display session 1
Resources:
Abstract
4305 - Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study
Presenter: Fabrice Barlesi
Session: Poster Display session 1
Resources:
Abstract
5128 - IO-Synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany
Presenter: Adrien Dixmier
Session: Poster Display session 1
Resources:
Abstract